|
gptkbp:instance_of
|
gptkb:protein
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Genzyme_Genetics
|
|
gptkbp:activities
|
Inhibits BCR-ABL tyrosine kinase
|
|
gptkbp:approves
|
gptkb:2007
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Tasigna
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:contraindication
|
QT prolongation
Severe hepatic impairment
Hypersensitivity to nilotinib
|
|
gptkbp:developed_by
|
gptkb:Novartis
|
|
gptkbp:dissolved
|
Slightly soluble in water
Soluble in DMSO
Soluble in methanol
|
|
gptkbp:formulation
|
gptkb:beer
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nilotinib
|
|
gptkbp:ingredients
|
C28 H29 N7 O2 S
|
|
gptkbp:interacts_with
|
CY P3 A4
CY P2 C9
CY P2 C8
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:is_atype_of
|
L01 X E05
|
|
gptkbp:is_monitored_by
|
Electrocardiogram (ECG)
Liver function tests
Complete blood count (CBC)
|
|
gptkbp:is_used_for
|
Chronic myeloid leukemia
|
|
gptkbp:manager
|
Oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:side_effect
|
gptkb:fandom
gptkb:Nausea
Diarrhea
Fatigue
Headache
Thrombocytopenia
Pancreatitis
Rash
Hyperglycemia
Hypocalcemia
Pulmonary hypertension
Skin reactions
Cardiovascular events
Vision changes
Leukopenia
Peripheral edema
Hypophosphatemia
Myelosuppression
|
|
gptkbp:targets
|
gptkb:BCR-ABL_fusion_protein
|
|
gptkbp:type_of
|
641571-10-0
|
|
gptkbp:weight
|
529.64 g/mol
|
|
gptkbp:year_created
|
gptkb:2000
|